Mobile-health Network Azioni (NASDAQ: MNDR)

Ultime notizie per Mobile-health Network (NASDAQ:MNDR) Azioni

Mobile-health Network

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. They provide their services on its MaNaDr platform, which is accessible via their mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users. The company's revenues are derived mainly from the provision of telemedicine and other services, sale of medicine and medical devices.

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network Solutions

News

Guidance

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

WIIM

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

Biotech

General

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

Earnings

Earnings Beats

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.08 by 3.7 percent. The company reported quarterly sales of $2.92 billion which beat the analyst consensus estimate of $2.83 billion by 3.29 percent. This is a 3.72 percent increase over sales of $2.82 billion the same period last year.

Earnings Misses

Intl Flavors & Fragrances Q3 2024 Adj EPS $1.04 Misses $1.08 Estimate, Sales $2.92B Beat $2.83B Estimate

Weyco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) (the "Company") announced that today its Board of Directors declared a special one-time cash dividend of $2.00 per share, for a total of approximately $19.0 million based on the number of shares currently outstanding. The dividend will be paid on January 2, 2025, to shareholders of record at the close of business on November 18, 2024.

Dividends

Weyco Group Declares Special Cash Dividend Of $2.00 Per Share, For A Total Of ~$19M Based On The Number Of Shares Currently Outstanding

Offerings

PLBY

Playboy Announced The Closing Of Its Sale Of 14.9M Newly Issued Shares In A Private Placement At A Price Of $1.50 Per Share For A Total Purchase Price Of $22.35M

SMCI

Super Micro Computer shares are trading lower after the company lowered its financial outlook.

MCHP

Microchip Sees Q3 2024 Adj. EPS $0.29-$0.32

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 Adj EPS guidance from $2.25-2.45 to $2.10-2.20 vs $2.26 analyst estimate. Lowers FY2024 sales outlook from $825.00 million-840.00 million to $800.00 million-805.00 million vs $824.37 million estimate.

HLIO

Helios Technologies Lowers FY2024 Adj EPS Guidance from $2.25-2.45 to $2.10-2.20 vs $2.26 Est; Lowers FY2024 Sales Guidance from $825.00M-840.00M to $800.00M-805.00M vs $824.37M Est

MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. The company reported quarterly sales of $797.000 million which beat the analyst consensus estimate of $794.160 million by 0.36 percent. This is a 10.25 percent decrease over sales of $888.000 million the same period last year.

MRC Global Q3 2024 Adj. EPS $0.22 Beats $0.20 Estimate, Sales $797.000M Beat $794.160M Estimate

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 GAAP EPS guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 analyst estimate..

Helios Technologies Lowers FY2024 GAAP EPS Guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 Est

Supermicro Sees Q2 FY2025 Net Sales $5.5B-$6.1B, GAAP EPS $0.48-$0.58, Non-GAAP EPS $0.56-$0.65

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is unchanged from the same period last year. The company reported quarterly sales of $150.50 million which missed the analyst consensus estimate of $152.30 million by 1.18 percent. This is a 6.40 percent decrease over sales of $160.78 million the same period last year.

SWIM

Latham Group Q3 EPS $0.05 Misses $0.06 Estimate, Sales $150.50M Miss $152.30M Estimate

Qualys Raises 2024 Adj EPS Guidance From $5.46- $5.62 To $5.81 - $5.91 (Est $5.57), Lifts Revenue Guidance From $597.5M - $601.5M To $602.9M - $605.9M (Est $599.362M)

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) affirms FY2025 sales outlook from $815.00 million-865.00 million to $815.00 million-865.00 million.

INNV

InnovAge Holding Affirms FY2025 Sales Guidance to $815.00M-865.00M  VS Est. 844.27M

XBP and MNTX among mid-day movers

New house bill to extend COVID-era telehealth flexibilities

Mobile-health Network expands services to Malaysia

Mobile-health Network Solutions Class A (MNDR) has released an update. Mobile-health Network Solutions, a leading telehealth provider in the Asia-P...

Mobile-health's Revenue Soars, Expands Amid IPO

ASTS, ALLO and CMCM are among premarket gainers

Mobile-health Network Solutions Class A (MNDR) has released an update. Mobile-health Network Solutions Class A issued a news release, but it appear...

Mobile-health Network Solutions: Release Lacks Details

Mobile-health Network Solutions receives Nasdaq notice of non-compliance

Mobile-health Network Solutions Class A (MNDR) has released an update. Mobile-health Network Solutions Class A has finalized an employment contract...

Mobile-health Inks Key Data Analyst Contract

IPO Roundup: KinderCare Learnings, Moove and more

MOBILE HLTH NWK reports FY results

ACTHF

AGBA

ALLO

AMWL

ASPCU

ASTS

BCAN

BENF

CMCM

DOGZ

EDBL

EYPT

FBGL

GLYC

HSDT

HUHU

IART

LHAI

LYRA

MAIA

MMAT

MNDR

MNTX

MOOV

MULN

NNVC

NRXP

NUVO

OCACU

PACS

PRFT

SARO

SEPN

SGBX

SILO

SNYRD

SUNH

TDOC

WYHG

Press Releases

A Message to Our Valued Stakeholders - We're Here for the Long Haul

Mobile-health Network Solutions Expands Services to Malaysia

Mobile-health Network Solutions Revenue Rises Approximately 120% in the First Six Months of Fiscal 2024

Streamline Today, Predict Tomorrow: MNDR's AI-Powered Health Operating System Optimizes Operations and Powers Predictive Healthcare

Ryde Group Ltd partners with Mobile-health Network Solutions

Mobile-health Network Solutions to Present at Sidoti Virtual Investor Conference August 14-15

Mobile-health Network Solutions Delinquency Notification Letter From Nasdaq

Mobile-health Network Solutions to Present at Two Financial Conferences for October 2024

Mobile-health Network Solutions (Nasdaq: MNDR) Fiscal 2024 Results to be Announced October 23rd, 2024; Conference Call to Discuss Results October 24th at 8:00 AM ET

Mobile-health Network Solutions Reports 77 Percent Revenue Increase for Fiscal Year 2024

RYDE

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

CareMax

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

23andMe Holding

ModivCare

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Vivos Therapeutics

Comments

Mobile-health Network

Notizie

Ultime notizie per Mobile-health Network (NASDAQ:MNDR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO